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Abstract 
Introduction: Delayed cerebral ischemia (DCI) is a frequent and serious complication of 
aneurysmal subarachnoid haemorrhage (SAH). The diagnosis of DCI lies primarily on the 
deterioration of the clinical state (neurological deficit), but can be difficult to detect in the 
comatose patient. Transcranial Dopper (TCD) and perfusion Computer Tomography with 
calculation of cerebral blood flow (CBF) and brain perfusion help with the diagnosis of DCI 
but their predictive values remain limited. The DCI mechanisms are complex, involving 
alteration of CBF, impaired cerebral autoregulation, brain energy dysfunction and activation 
of pro-inflammatory mediators. The use of novel techniques for advanced intracranial 
monitoring (including brain tissue PO2  and cerebral microdialysis) offer the opportunity to 
study in detail DCI physiopathology and might help detecting DCI and guiding therapeutic 
interventions in patients suffering from SAH. 
 
General objectives: The main objective of this study was to examine the relationship between 
global CBF – measured with TCD and perfusion-CT – and regional brain metabolism, 
measured with the brain tissue oxygen (PbtO2) probe and the cerebral microdialysis (CMD) 
technique. 
 
Specific objectives:  
To examine the relationship between: 
- DCI and the brain tissue oxygen pressure reactivity index (ORx), which  is calculated as the 
moving linear correlation coefficient between PbtO2 and CPP (=mean arterial pressure – 
intracranial pressure). The ORx is considered as a surrogate marker of the cerebral 
autoregulation state; 
- ORx and CBF, calculated with the perfusion-CT; 
- ORx and CMD markers of brain energy metabolism (including the lactate/pyruvate ratio and 
glucose). 
 
Methods: Retrospective analysis of an ongoing cohort database of patients with coma (defined 
by a Glasgow Coma Scale (GCS) ≤ 8) after aneurysmal SAH, with an abnormal CT-scan 
(Fisher grade II-IV), who underwent intracranial monitoring with PbtO2 and CMD as part of 
standard care. Intracranial monitoring was inserted after admission (2 ±1 days). A total of 21 
patients were admitted in the Intensive Care Department with poor-grade SAH and underwent 
imaging and aneurysm securisation (with surgical clipping or endovascular coiling).  Cerebral 
microdialysis allows to measure every hour, through a catheter placed in the cerebral 
parenchyma (white matter), the extracellular concentration of the main brain metabolites 
(glucose, lactate, pyruvate, lactate/pyruvate ratio). The DCI is diagnosed with the TCD and 
the perfusion-CT. The CBF (derived from the cerebral blood volume and the mean transit 
time) was calculated with the perfusion-CT, with a CBF < 32ml/100g/min that was used as 
the threshold for brain oligemia. Brain cell hypoxia was defined as a PbtO2 <20mmHg and/or 
a CMD lactate/pyruvate-ratio >40. The different variables were compared by univariate 
analysis using a Wilcoxon test for comparisons. The relationship between variables was 
analysed with the Pearson’s R linear correlation coefficient factor. 
 
Expected results: From a clinical standpoint, if a relationship between regional brain 
physiological variables and global cerebral blood flow can be demonstrated, this could serve 
as a validation of PbtO2 and cerebral microdialysis monitoring as complementary tools for the 
diagnosis and the management of DCI in comatose SAH patients. From a pathophysiological 
standpoint, this study will provide new insights concerning the relationship between cerebral 
blood flow, brain oxygenation and cerebral energy metabolism in the acute phase of SAH. 
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1 Introduction: 
Symptomatic vasospasm with delayed cerebral ischemia (DCI) is a frequent complication of 
aneurysmal subarachnoid haemorrhage (SAH), occurring in about 30 to 70% of patients1, and 
is associated with substantial morbidity and mortality2. Diagnosis and management of DCI 
remains a challenging task for clinicians.  Clinical examination is the first trigger to 
intervention however it is not always reliable in patients with coma after SAH. Additional 
diagnostic tools include perfusion CT and trans-cranial Doppler3,4 but their predictive value 
remains limited5. 
Given the limited value of the available tools, additional techniques have been developed 
particularly for the diagnosis and the management of DCI in comatose SAH patients. These 
include so-called multimodal monitoring with the use of invasive intra-parenchymal brain 
tissue oxygen (PbtO2) probes and the implementation of the cerebral microdialysis technique 
(see chapter 3.5 and 3.6). These tools however require further investigation and validation in 
the clinical setting. They offer a unique technology to better explore the complex 
pathophysiology of SAH and allow a surrogate marker for the assessment of cerebral blood 
flow (CBF) and patient cerebral autoregulatory status at the bedside.  
 
1.1 Delayed cerebral ischemia: pathophysiology 
 
Subarachnoid haemorrhage due to a ruptured intracerebral aneurysm causes early secondary 
brain injury with increased intracranial pressure, brain shift and herniation6. Delayed cerebral 
ischemia due to vasospasm is the most common and one of the most severe complications 
after SAH, generally occurring at 5-10 days from acute injury. The exact mechanisms of DCI 
after SAH are complex and still not completely understood7,8. Among other factors, the 
impairment of cerebral autoregulation has been recognized as an important pathophysiologic 
determinant of DCI. Like almost any other vascular beds, the brain’s vasculature has the 
intrinsic protective ability to maintain adequate CBF relatively independent of fluctuations of 
systemic arterial pressure. This process is known as the cerebral pressure autoregulation or 
cerebro-vascular pressure reactivity. Below or above a range of vascular pressure (50 mmHg 
and 160 mmHg respectively) the CBF will progressively lack its ability to remain 
independent from the blood pressure and will passively follow the pressure changes. 
After SAH, cerebral autoregulation is frequently impaired leaving the brain more susceptible 
to secondary ischemic insults9–13. Impaired cerebro-vascular pressure reactivity has been 
linked with DCI after SAH in clinical studies14–16. Monitoring of regional PbtO2 gives an 
indirect measurement of CBF17. The on-line linear correlation between PbtO2 and the cerebral 
perfusion pressure (CPP= intracranial pressure (ICP) - mean arterial pressure, MAP) is an 
indicator of the cerebro-vascular pressure reactivity and of the adequacy of cerebral 
autoregulation after SAH. This index is called the oxygen pressure reactivity index or ORx. In 
normal conditions CPP and PbtO2 are not correlated and therefore the ORx is close to 0. In 
conditions of impaired autoregulation, when CBF follows passive changes of systemic 
pressure, PbtO2 and CPP are linearly correlated (and thus the ORx is above 0.3)18. 
 
1.2 Hypothesis, objectives and expected values  
 
The primary endpoint of this study was to examine the relationship of global CBF assessed 
with perfusion CT with regional intracranial monitoring using PbO2 and intra-cerebral 
microdialysis. From a mechanistic point of view, this study will give new data concerning the 
relationship between cerebral blood flow, oxygenation and metabolism after SAH. From a 
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clinical point of view, if we demonstrate a relationship between regional physiological brain 
variables and global CBF, this would validate PbtO2 and CMD as complementary tools for the 
diagnosis and management of DCI in comatose patients after SAH, in whom standard 
diagnostic tools are less reliable.  
 
1.3 Study type 
 
Retrospective analysis of a cohort database of patients admitted to the Service de Médecine 
Intensive Adulte (SMIA), at the Lausanne University Hospital (CHUV), Lausanne, 
Switzerland. The data analysis was conducted at the Neuroscience Critical Care Research 
Group, SMIA, CHUV, under the leadership of Mauro Oddo, MD, médecin-adjoint, PD-MER. 
Authorization for the study was obtained from the Clinical Research Ethical Committee at the 
University of Lausanne, with waiver of patient consent given the retrospective nature of the 
study. 
 
1.4     Patients 
 
Subjects were part of an ongoing cohort database of patients with coma (defined by a 
Glasgow Coma Scale (GCS) ≤ 8) after aneurysmal SAH with an abnormal CT-scan (Fisher 
grade II-IV) who underwent intracranial monitoring with ICP, PbtO2 and cerebral 
microdialysis as part of standard care, according to a written institutional algorithm.  
Intracranial monitoring was inserted soon after hospital admission (2 ±1 days). A total of 21 
patients were admitted in the Intensive Care Department with poor-grade SAH. Aneurysm 
rupture was treated with surgical clipping or endovascular coiling.   
 
1.5     Management 
 
Patients were treated according to the protocol for the management of SAH from the CHUV. 
Patients were admitted after a post-operative procedure (coiling or clipping). Patients were 
sedated with propofol and sufentanil, and mechanically ventilated aiming to PaO2 90-100 
mmHg and PaCO2 35-40 mmHg. Brain physiological targets were set to maintain ICP <20 
mmHg, cerebral perfusion pressure (CPP=mean arterial pressure, measured via an intra-
arterial catheter – ICP) > 60 mmHg, and PbtO2 >20 mmHg.  
The aim was the prevention and treatment of the secondary cerebral lesion and the prevention 
of the vasospasm responsible of the delayed cerebral ischemia. All patients received oral or 
intravenous nimodipine for prophylaxis of DCI. Medical therapy of DCI consisted of 
hemodynamic augmentation with fluids (isotonic lactate), vasopressors (norepinephrine), and 
inotropes (milrinone). DCI refractory to medical therapy was managed by interventional 
radiology with in situ infusion of vasodilators (nimodipine or milrinone) and mechanical 
angioplasty when required.  
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2 Intracranial monitoring 
2.1  Brain Oxygen 
 
PbtO2 was measured using the Licox® catheter (Integra Neurosciences, Plainsboro, NJ, USA). 
Brain hypoxia can lead to secondary lesion. It has therefore become necessary to monitor the 
brain oxygen pressure to distinguish a normal and impaired oxygen supply. In the last decade, 
the monitoring of brain oxygen pressure has shown its clinical utility. The brain oxygen 
pressure is known as the arterio-venous oxygen tension difference (AVTO2) times the 
cerebral blood flow (CBF): 
PbtO2= AVTO2 × CBF 
 
AVTO2 is defined as the arterial oxygen pressure (PaO2) minus the venous oxygen pressure 
(PvO2). PbtO2 represents the interaction between plasma oxygen tension and CBF19. 
There are four different ways to measure PbtO2: jugular bulb oximetry, direct brain tissue 
oxygen tension measurement, near infrared spectroscopy and oxygen-15 positron emission 
tomography (PET). Attention will be given to the direct brain tissue oxygen tension 
measurement, as it is the technique which has been used for our patients and it is available at 
patient bedside.  
The Licox PbtO2 probe consists of a catheter that is inserted during neurosurgery and placed, 
for SAH patients, in the parenchymal region where vasospasm and DCI is more likely to 
develop, according to the location of the ruptured aneurysm localisation and the distribution 
of the SAH. The Licox PbtO2 probe is based on the Clarke principle. Parenchymal oxygen 
diffuses through a membrane and is reduced at the contact of the cathode producing a voltage 
change. The diffusion of the oxygen is proportional to its concentration and the voltage 
change is proportional to the amount of reduced oxygen. This process is temperature 
dependent and requires constant calibration to patient body temperature. 
 
2.2  Cerebral microdialysis 	  
 
Cerebral microdialysis (CMD) is a minimally invasive technique that allows a bedside online 
analysis (every hour) of brain tissue biochemistry during neurointensive care. The device 
consists of a micro-catheter (CMA 70 catheter, M Dialysis AB®, Stockholm, Sweden) that is 
placed in the brain parenchyma, close to ICP and PbtO2 monitors. The catheter has at its tip a 
semi-permeable dialysis membrane through which an artificial cerebrospinal fluid is infused 
at a constant slow flow rate (0.3μl/min), using a controlled pump (CMA 106® pump). Several 
metabolites (including glucose, lactate, pyruvate, glutamate, glycerol) can be measured in 
patient’s brain extracellular fluid through the semi-permeable membrane following a 
concentration gradient according to the diffusion principles (20kDa cut-off). Once at 
equilibrium, the fluid (dialysate) is collected and analysed at the bedside every hour using a 
kinetic enzymatic methodology (ISCUS flex® analyser). 
All intracranial probes were inserted in the operating room by a neurosurgeon through a 
triple-lumen bolt (Integra Neurosciences), and placed into apparently normal brain 
parenchyma (sub-cortical white matter), in the right frontal lobe (see Figure 1)20. A CT scan 
was performed at ≈ 24 hours to confirm the correct placement of intracranial monitors.  
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2.3 Calculation of the Index of Brain Tissue Oxygen Pressure Reactivity 
(ORx) for the Assessment of the Autoregulatory Status 
 
The ability of the brain to maintain PbO2 despite wide CPP changes is known as the cerebro-
vascular pressure reactivity 21. The index of PbtO2 pressure reactivity (ORx) is calculated as 
the moving linear (Pearson’s) correlation coefficient between values of CPP and PbtO2 from 
the previous 60 minutes of monitoring22. The ORx is an indicator of the cerebral 
autoregulatory status, with values going from -1 to 1. An ORx which is close to 0 indicates a 
normal autoregulatory status, while a positive high ORx (>0.3) indicates an impairment of 
cerebro-vascular pressure reactivity and an abnormal cerebral autoregulation, where PbtO2 
passively follows CPP and a much higher risk of secondary cerebral ischemic insults9 and 
worse outcome after TBI18, SAH9, and stroke23. 
  
The use of cerebral microdialysis has been described in TBI and SAH patients17. While the 
technique is well established in patients with traumatic brain injury, data regarding SAH 
patients are still relatively limited. The measure of lactate, pyruvate, lactate/pyruvate ratio 
combined to the partial pressure brain tissue oxygen (PbtO2) readings, and glucose has been 
suggested to be useful to detect secondary ischemia/hypoxia due to vasospasm24,25. In general, 
high mean lactate/pyruvate ration and low glucose is correlated with ischemia and poor 
outcome. Others have related a high lactate without hypoxia/ischemia26. Data combining 
cerebral microdialysis with PbtO2 are particularly limited: they warrant further investigation 
since they could help understanding the pathophysiology of SAH and might improve the 
management of DCI following SAH. 
 
Brain perfusion CT was performed using a multi-detector row CT Lightspeed (GE medical 
systems, Milwaukee, WI, USA). Scanning was initiated 5 seconds after injection of 50 ml of 
iohexol (300 mg/mL of iodine; GE Healthcare), at a rate of 5 mL/sec, with the following 
parameters: 80 kV, 240 mAs, 0.4 rotations/sec, total duration of 50 sec. The series evaluated 
sixteen adjacent 5-mm-thick sections of brain parenchyma. Post-processing of PCT data was 
performed by two experienced neuro-radiologists, using a dedicated software (Brilliance 
Workspace Portal®, Philips medical systems, Cleveland, OH, USA) which employs the 
central volume principle using deconvolution to measure the mean transit time (MTT); 
cerebral blood volume (CBV) is calculated from the time-enhancement curves, and cerebral 
Figure 1. Location of 
cerebral microdialysis 
and brain tissue PO2 
catheters. One 
illustrative example of 
probe location in the 
right frontal subcortical 
white matter, with close 
positioning of CMD and 
brain tissue PO2 
catheters 
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blood flow (CBF) is derived from the equation CBF = CBV/MTT. For each PCT, one region 
of interest (ROI) was manually drawn around the probe (surface area ∼ 50 mm2) to calculate 
regional CBF, and two others ROI (one for each hemisphere) of approximately 250 mm2 were 
selected above the ventricular system and included anterior and middle cerebral artery 
territories (global CBF), as described by Sala et al20.  Since probes were located in the white 
matter, supra-ventricular ROI were drawn in areas of predominant white matter to allow 
concordant measurements of global supra-tentorial CBF in the same type of tissue. 
Calculation of global and regional CBF was performed by an experienced neuro-radiologist, 
blinded to intracranial monitoring data.  
 
 
3 Data collection and processing  
 
The index of PbtO2 pressure reactivity (ORx) is calculated as the moving linear correlation 
coefficient (Pearson’s r) between CPP and PbtO2 from the previous 60 minutes of 
monitoring22.  Artefacts caused by temporary disconnection of catheters or nursing 
interventions were manually eliminated from the data sets, and ORx was calculated after 
artefacts elimination. 
PbtO2 and ORx data were subsequently manually matched to CMD data. Brain physiologic 
variables were matched to perfusion CT data during the time window that we considered as 
the most representative of the patient brain state, i.e. we included samples obtained at the time 
of perfusion CT, plus samples from the 3 hours previous and the 3 hours following the CT 
time (total of 7 epochs). The same procedure was applied to match brain physiologic variables 
to trans-cranial Doppler (TCD) data. If data close to the perfusion CT or TCD were missing, 
then we extended the time-period up to maximum 3 hours for perfusion CT and 8 hours for 
TCD. 
 
3.1 Statistical analysis  
 
Data analysis was performed using JMP-10R (SAS Institute, Cary, NC, USA). A p value < 
0.05 was considered statistically significant. Data were expressed as median interquartile 
range. Associations of cerebral physiologic and metabolic variables with CT results were 
analyzed with univariate analysis, using non-parametric Wilcoxon test for continuous 
variables and Chi-square test for categorical variables.   
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4 Results 
4.1 Patients Characteristics 
 
The studied population consisted of 21 consecutive patients with the diagnosis of poor-grade 
comatose aneurysmal SAH admitted in the intensive care unit (ICU) of the CHUV (Service de 
Médecine Intensive Adulte SMIA). 
 
Table 1.  Patients Characteristics  
Age, years 57 (40-72) 
Female gender, nr/total nr. 15/21 
Glasgow Coma Scale 6 (3-14) 
Duration of brain physiologic monitoring, hrs 133 (26-2897) 
Time from SAH to monitoring, hrs 23 (5-144) 
Endovascular coiling/Surgical clipping 10/11 
Delayed Cerebral Ischemia (DCI) 11/21 
 
Data are expressed as median (range). 
 
 
4.2 Relationship between ORx index and DCI 
 
Average daily ORx from day 1 to 6 of the DCI group compared to the non-DCI group are 
presented in Figure 2.  
 
 
 
Most importantly from the clinical standpoint, ORx was high in the two subgroups in the 
early phase (suggesting impaired cerebro-vascular pressure reactivity in the first 24 hrs 
following SAH), but then tended to normalization in patients with no DCI, while it remained 
high and even increased in those who subsequently developed DCI (see above average daily 
ORx between the two subgroups; DCI n=11 vs. no-DCI n=10, Figure 2). 
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Compared to patients with no DCI (n=10), subjects with a confirmed diagnosis of DCI (n=11) 
had higher ORx values (median 0.34 interquartile [0.15-0.58] vs. 0.41 [0.17-0.62]; p=0.0236, 
see Summary Table).  
 
 
4.3 Relationship between Cerebral Blood Flow and ORx 
 
In order to assess the global CBF and, by extension, the presence of vasospasm, 18 perfusion-
CT/angioCT among 10 patients and 31 transcranial Doppler among 9 patients were 
performed. The ORx values 3 hours before the exam and 3 hours after the exam were studied. 
We compared the ORx values for the exam that confirmed the absence/presence of a 
vasospasm.  
 
4.3.1 Perfusion CT assessment of Cerebral Blood Flow 
 
In comparison with the normal perfusion CT group, the perfusion CT group that diagnosed an 
oligemic CBF showed a trend towards higher ORx values (mean values: 0.5 [0.27; 0.7] vs. 
0.36 [0.18; 0.63] p=0.08). 
 
4.3.2 Trans-cranial Doppler assessment of Cerebral Blood Flow 
 
In the same way, in comparison to the normal transcranial Doppler group, the transcranial 
Doppler group that diagnosed pathologically elevated CBF velocities indicative of 
symptomatic vasospasm showed a trend towards higher ORx values (mean values: 0.505 
[0.26; 0.72] vs. 0.43 [0.2; 0.61] p=0.065). 
 
4.4 Relation between indexes of regional cerebral autoregulation and 
microdialysis biomarkers 
 
In order to study both parameters, the ORx values were matched to every single MD 
sampling. Attention was brought to the Lactate/Pyruvate ratio and glucose 
 
4.4.1 Lactate Pyruvate ratio and ORx values 
 
A LPR> 40 is often used as a threshold of cerebral hypoxia or ischemia and is associated with 
a poor outcome5;6;7. ORx values were dichotomized into >0.3 (impaired autoregulation) or 
<0.3 (preserved autoregulation) in order to assess the LPR level corresponding to each group. 
Higher LPR were found when the ORx value was >0.3 (mean values 29 [25; 34]; vs. 27 [24; 
33] p=0.0930). 
 
4.4.2 MD Glucose and ORx values 
 
Higher ORx values were found when glucose level was below 1mM, and when the perfusion 
CT diagnosed vasospasm with cerebral hypoperfusion also statistically significant and 
clinically relevant lower cerebral glucose levels were found (mean value 1.1 [0.11; 4.38] vs. 
0.79 [0.37; 2.87]; p=0.03).   
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4.5 Summary Table  
 
Illustration of the differences in brain physiologic variables between patients with vs. without 
DCI, based on clinical, neuro-radiological and TCD findings. Results are expressed as 
medians (interquartile ranges). 
 
 
Variable 
 
DCI group 
N=11 
 
No-DCI group 
N=10 
 
 
P value 
ORx 0.41 [0.15-0.58] 0.34 [0.17-0.62] 0.02 
 Oligemic perfusion CT 
 
Normal perfusion CT 
 
 
CMD Glucose 0.79 mM [0.37; 2.87] 1.1mM [0.11; 4.38] 0.03 
ORx 0.5 [0.27; 0.7] 
 
0.36 [0.18; 0.63] 0.08 
 Positive TCD for 
vasospasm 
Negative TCD for vasospasm 
 
 
ORx 0.505 [0.26; 0.72] 0.43 [0.2; 0.61] 0.065 
 Impaired ORx>0.3 Preserved ORx<0.3 
 
 
CMD 
Lactate/pyruvate 
ratio  
28.895 [24.85; 34.44] 27.91 [24.02; 32.95] 0.0930 
4.6 Autoregulation 48 Hours before Vasospasm 	  
Four patients were monitored with a PbtO2 probe at the time they underwent a vasospasm. 
The course of the ORx values during the 48 hours before the vasospasm was rising in the four 
studied cases, suggesting progressive impairment of cerebro-vascular pressure reactivity over 
time (Figure 3).  
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5 Discussion and conclusions 
5.1 Impaired cerebrovascular autoregulation and delayed cerebral 
ischemia 
 
Cerebrovascular autoregulation differences, measured by the index of brain tissue oxygen 
pressure reactivity, are observed between patients who suffered from a DCI and those who 
did not. This intrinsic cerebral mechanism to control blood flow relatively independent of the 
CPP was significantly diminished in those who underwent a DCI. Similarly, Jaeger et al. 
demonstrated a difference in cerebrovascular autoregulation in patients with a favourable and 
unfavourable outcome9. The trend towards a higher ORx when neuroimaging techniques 
diagnosed an impaired CBF supports previous results by other groups. Our study also support 
the concept that impairment in cerebrovascular autoregulatory capacities are an essential 
pathophysiological factor leading to DCI.  
Trends of higher ORx values were found when perfusion-CT and TCD showed signs of 
symptomatic vasospasm. These findings show the potential role of bedside PbtO2 and ORx 
monitoring as a surrogate marker of cerebral autoregulation and potentially to detect DCI. 
Although still controversial27, our preliminary findings are encouraging since they support the 
clinical use of the bedside monitoring of PbtO2 and ORx values and their validity in providing 
precious information concerning DCI and patient prognosis 9,10,14,15,28–31.  
 
5.2 The relationship between cerebral blood flow autoregulation and 
brain metabolism 
 
As seen in other studies32,33 a decreased microdialysis-glucose concentration when regional 
PbtO2 tends to reach 10mmHg or below, as seen in vasospasm, was a relevant finding. It is 
now believed that the aetiology of this low MD-glucose is multifactorial34. There is a 
reduction of the oxidative neuronal metabolism and an increase in anaerobic glucose 
metabolism. However, in some cases that showed a poor correlation with positron emission 
tomography (PET)-defined ischemia and low MD-glucose, this change may be associated 
with hyperglycolysis rather than a reduction of the oxygen and glucose supply because of 
reduced cerebral perfusion35. 
The LPR>40 is currently used as a threshold for brain cell hypoxia;6;7. It has been repeatedly 
proven that the injured brain could use other substrate than glucose to maintain its activity, 
14	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including lactate. A significant LPR difference couldn’t be assessed in the ORx subgroups. 
However it is now believed that other mechanisms than ischemia (i.e. increased glycolysis) 20 
might explain elevated lactate and pyruvate. 
 
5.3 Study limitations 
 
Our CMD and PbtO2 data come from a regional monitoring, and thus may not reflect the 
global metabolism. Our results may have been disturbed by the fact that the PbtO2 and CMD 
measurements are easily displaced inducing long period of incorrect readings. Our patient 
cohort is limited in size and despite the fact that our data were collected prospectively it was 
analysed retrospectively. The results of this study need to be considered as preliminary but 
encourage future investigation and prospective studies to confirm the value of PbtO2 
monitoring after SAH.  
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